This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Nuclear receptor subfamily 5 group A member 2 (NR5A2; LRH-1)	<p>Mouse and <i>in vitro</i> studies identified an LRH-1 antagonist that could be useful for treating cancer. In <i>in vitro</i> binding studies, the compound bound LHR-1 with a K_d value of about 1.8 μM. In human cancer cells, the compound inhibited proliferation of LHR-1-positive cell lines. Next steps could include evaluating the LRH-1 antagonist in mouse xenograft models.</p> <p>SciBX 6(23); doi:10.1038/scibx.2013.573 Published online June 13, 2013</p>	Patent and licensing status not available	<p>Benod, C. <i>et al. J. Biol. Chem.</i>; published online May 10, 2013; doi:10.1074/jbc.M112.411686 Contact: Robert Fletterick, University of California, San Francisco, Calif. e-mail: robert.fletterick@ucsf.edu</p>